Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10224023 | 0.87 | TGFBR1 (0.47) | PRMT5WDR77MAPK13MAPK12MAPK11 | |
| SCHEMBL477106 | 0.86 | PRMT5 (0.47) | PRMT5WDR77MAPK13MAPK12MAPK11 | |
| SCHEMBL3121310 | 0.85 | MAPK14 (0.62) | MAPK13MAPK12MAPK11MAPK14CSNK1E | |
| SCHEMBL477158 | 0.82 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL477168 | 0.81 | PRMT5 (0.49) | PRMT5WDR77CSNK1E | |
| SCHEMBL477159 | 0.80 | PRMT5 (0.43) | PRMT5WDR77MAPK13MAPK12MAPK11 | |
| SCHEMBL477098 | 0.78 | PRMT5 (0.49) | PRMT5WDR77MAPK13MAPK12MAPK11 | |
| SCHEMBL5126526 | 0.77 | MAPK14 (0.60) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL477039 | 0.76 | PRMT5 (0.45) | PRMT5WDR77CSNK1ECNR1 | |
| SCHEMBL477105 | 0.76 | PRMT5 (0.55) | PRMT5WDR77CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312934-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | NR3C1, CNKSR1, NR3C2 | PRMT5 388/4885WDR77 1353/4885MAPK13 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.